Mitochondrial fragmentation and dysfunction is a key contributor to multiple clinical pathologies, including neurodegenerative disorders, sepsis, and myocardial infarction.
Researchers at Stanford University have discovered a first-in-class covalent inhibitor that binds to activated Fis1 and prevents mitochondrial fission and dysfunction.
Stanford researchers in the laboratory of Dr. Daria Mochly-Rosen have developed novel small molecules for modulating ALDH2 (mitochondrial aldehyde dehydrogenase-2).